{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T16:52:25Z","timestamp":1790009545107,"version":"4.0.1"},"reference-count":29,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaloncologyonline.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Oncology"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.clon.2023.02.014","type":"journal-article","created":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T17:30:03Z","timestamp":1677691803000},"page":"446-453","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["The Effect of Renin\u2013Angiotensin\u2013Aldosterone System Inhibitors on Outcomes of Patients Treated with Immune Checkpoint Inhibitors: a Retrospective Cohort Study"],"prefix":"10.1016","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5757-6161","authenticated-orcid":false,"given":"C.-H.","family":"Chiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3783-0409","authenticated-orcid":false,"given":"S.-S.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.-C.","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1744-9141","authenticated-orcid":false,"given":"C.-H.","family":"Chiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.-Y.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.-J.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5388-9112","authenticated-orcid":false,"given":"X.Y.","family":"See","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7174-2410","authenticated-orcid":false,"given":"C.-Y.","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.P.","family":"Hsia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7910-2338","authenticated-orcid":false,"given":"C.-H.","family":"Chiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.-M.","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clon.2023.02.014_bib1","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1146\/annurev-pathol-042020-042741","article-title":"Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance","volume":"16","author":"Bagchi","year":"2021","journal-title":"Annu Rev Pathol"},{"issue":"9","key":"10.1016\/j.clon.2023.02.014_bib2","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1158\/2159-8290.CD-18-0367","article-title":"Fundamental mechanisms of immune checkpoint blockade therapy","volume":"8","author":"Wei","year":"2018","journal-title":"Cancer Discov"},{"issue":"12","key":"10.1016\/j.clon.2023.02.014_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s12276-018-0191-1","article-title":"Immune checkpoint inhibitors: recent progress and potential biomarkers","volume":"50","author":"Darvin","year":"2018","journal-title":"Exp Mol Med"},{"issue":"4","key":"10.1016\/j.clon.2023.02.014_bib4","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","article-title":"Primary, adaptive, and acquired resistance to cancer immunotherapy","volume":"168","author":"Sharma","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.clon.2023.02.014_bib5","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ejca.2020.09.033","article-title":"Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and validation of a novel prognostic index","volume":"142","author":"Buti","year":"2021","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1016\/j.clon.2023.02.014_bib6","article-title":"Integrated analysis of concomitant medications and oncological outcomes from PD-1\/PD-L1 checkpoint inhibitors in clinical practice","volume":"8","author":"Cortellini","year":"2020","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.clon.2023.02.014_bib7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2022.07.006","article-title":"Efficacy of cationic amphiphilic antihistamines on outcomes of patients treated with immune checkpoint inhibitors","volume":"174","author":"Chiang","year":"2022","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clon.2023.02.014_bib8","doi-asserted-by":"crossref","unstructured":"Chiang CH, Chen YJ, Chiang CH, Chen CY, Chang YC, Wang SS et\u00a0al. Effect of metformin on outcomes of patients treated with immune checkpoint inhibitors: a retrospective cohort study. 2023 Cancer Immunol Immunother (in press).","DOI":"10.1007\/s00262-022-03363-6"},{"issue":"410","key":"10.1016\/j.clon.2023.02.014_bib9","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aan5616","article-title":"Targeting the renin-angiotensin system to improve cancer treatment: implications for immunotherapy","volume":"9","author":"Pinter","year":"2017","journal-title":"Sci Transl Med"},{"issue":"2","key":"10.1016\/j.clon.2023.02.014_bib10","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.immuni.2012.10.015","article-title":"Angiotensin II drives the production of tumor-promoting macrophages","volume":"38","author":"Cortez-Retamozo","year":"2013","journal-title":"Immunity"},{"issue":"4","key":"10.1016\/j.clon.2023.02.014_bib11","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.21873\/anticanres.14980","article-title":"Impact of renin-angiotensin system inhibitors on the efficacy of anti-PD-1\/PD-L1 antibodies in NSCLC patients","volume":"41","author":"Tozuka","year":"2021","journal-title":"Anticancer Res"},{"issue":"6","key":"10.1016\/j.clon.2023.02.014_bib12","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.clgc.2021.04.002","article-title":"Angiotensin blockade modulates the activity of PD1\/L1 inhibitors in metastatic urothelial carcinoma","volume":"19","author":"Jain","year":"2021","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.clon.2023.02.014_bib13","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.ejca.2021.12.024","article-title":"Renin-angiotensin-aldosterone system inhibitors and survival in patients with hypertension treated with immune checkpoint inhibitors","volume":"163","author":"Drobni","year":"2022","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clon.2023.02.014_bib14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/CCI.19.00013","article-title":"Characterizing the feasibility and performance of real-world tumor progression end points and their association with overall survival in a large advanced non-small-cell lung cancer data set","volume":"3","author":"Griffith","year":"2019","journal-title":"JCO Clin Cancer Inform"},{"issue":"1","key":"10.1016\/j.clon.2023.02.014_bib15","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1186\/s40425-019-0805-8","article-title":"Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors","volume":"7","author":"Das","year":"2019","journal-title":"J\u00a0Immunother Cancer"},{"issue":"6","key":"10.1016\/j.clon.2023.02.014_bib16","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.jaad.2018.05.035","article-title":"Characterization of dermatitis after PD-1\/PD-L1 inhibitor therapy and association with multiple oncologic outcomes: a retrospective case-control study","volume":"79","author":"Min Lee","year":"2018","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"12","key":"10.1016\/j.clon.2023.02.014_bib17","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.jchf.2016.08.001","article-title":"Hypertension, obesity, diabetes, and heart failure-free survival: the cardiovascular disease lifetime risk pooling project","volume":"4","author":"Ahmad","year":"2016","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.clon.2023.02.014_bib18","doi-asserted-by":"crossref","first-page":"l223","DOI":"10.1136\/bmj.l223","article-title":"Trends in survival after a diagnosis of heart failure in the United Kingdom 2000\u20132017: population based cohort study","volume":"364","author":"Taylor","year":"2019","journal-title":"BMJ"},{"issue":"12","key":"10.1016\/j.clon.2023.02.014_bib19","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1093\/jjco\/hyac150","article-title":"The incidence and risk of cardiovascular events associated with immune checkpoint inhibitors in Asian populations","volume":"52","author":"Chiang","year":"2022","journal-title":"Jpn J Clin Oncol"},{"issue":"6","key":"10.1016\/j.clon.2023.02.014_bib20","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1136\/heartjnl-2022-321545","article-title":"Impact of sodium-glucose cotransporter-2 inhibitors on heart failure and mortality in patients with cancer","volume":"109","author":"Chiang","year":"2023","journal-title":"Heart"},{"issue":"11","key":"10.1016\/j.clon.2023.02.014_bib21","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1038\/nrc2945","article-title":"The renin-angiotensin system and cancer: old dog, new tricks","volume":"10","author":"George","year":"2010","journal-title":"Nat Rev Cancer"},{"issue":"9","key":"10.1016\/j.clon.2023.02.014_bib22","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1093\/carcin\/bgn171","article-title":"The renin-angiotensin system and malignancy","volume":"29","author":"Ager","year":"2008","journal-title":"Carcinogenesis"},{"issue":"4","key":"10.1016\/j.clon.2023.02.014_bib23","first-page":"1073","article-title":"The angiotensin-I-converting enzyme inhibitor perindopril suppresses tumor growth and angiogenesis: possible role of the vascular endothelial growth factor","volume":"7","author":"Yoshiji","year":"2001","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clon.2023.02.014_bib24","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1038\/ncomms3516","article-title":"Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels","volume":"4","author":"Chauhan","year":"2013","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.clon.2023.02.014_bib25","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1172\/JCI69666","article-title":"Angiotensin II-dependent TGF-\u03b2 signaling contributes to Loeys-Dietz syndrome vascular pathogenesis","volume":"124","author":"Gallo","year":"2014","journal-title":"J\u00a0Clin Invest"},{"issue":"8","key":"10.1016\/j.clon.2023.02.014_bib26","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1038\/cr.2013.88","article-title":"ROS sets the stage for macrophage differentiation","volume":"23","author":"Covarrubias","year":"2013","journal-title":"Cell Res"},{"issue":"12","key":"10.1016\/j.clon.2023.02.014_bib27","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1038\/ni.3868","article-title":"Oxidative stress controls regulatory T cell apoptosis and suppressor activity and PD-L1-blockade resistance in tumor","volume":"18","author":"Maj","year":"2017","journal-title":"Nat Immunol"},{"issue":"3","key":"10.1016\/j.clon.2023.02.014_bib28","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jdermsci.2010.10.004","article-title":"Elevated risk of second primary cancer in patients with cutaneous malignant melanoma: a nationwide cohort study in Taiwan","volume":"60","author":"Hwang","year":"2010","journal-title":"J\u00a0Dermatol Sci"},{"issue":"21","key":"10.1016\/j.clon.2023.02.014_bib29","first-page":"591","article-title":"Vital signs: melanoma incidence and mortality trends and projections \u2013 United States, 1982\u20132030","volume":"64","author":"Guy","year":"2015","journal-title":"Morb Mortal Wkly Rep"}],"container-title":["Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0936655523000614?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0936655523000614?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T15:52:29Z","timestamp":1760543549000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0936655523000614"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":29,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["S0936655523000614"],"URL":"https:\/\/doi.org\/10.1016\/j.clon.2023.02.014","relation":{},"ISSN":["0936-6555"],"issn-type":[{"value":"0936-6555","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Effect of Renin\u2013Angiotensin\u2013Aldosterone System Inhibitors on Outcomes of Patients Treated with Immune Checkpoint Inhibitors: a Retrospective Cohort Study","name":"articletitle","label":"Article Title"},{"value":"Clinical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clon.2023.02.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier Ltd on behalf of The Royal College of Radiologists.","name":"copyright","label":"Copyright"}]}}